Rotigotine is a nonergot dopamine agonist indicated for the treatment of parkinson's disease, among other approved uses. It is available as transdermal patches and kits. MedsAcross supplies Rotigotine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease. Moderate-to-severe primary Restless Legs Syndrome Parkinson's Disease (PD) NEUPRO is indicated for the treatment of Parkinson's disease. Restless Legs Syndrome (RLS) NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.
Source: US FDA prescribing information
Rotigotine is a non-ergoline dopamine agonist. The precise mechanism of action of rotigotine as a treatment for Parkinson's disease is unknown, although it is thought to be related to its ability to stimulate dopamine receptors within the caudate-putamen in the brain. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine receptors.
Source: US FDA prescribing information
Parkinson's disease: Initially, 2 mg/24 hours for early-stage disease or 4 mg/24 hours for advanced-stage disease. The dose may be increased as needed by 2 mg/24 hours at weekly intervals, up to 6 mg/24 hours for early- stage disease and up to 8 mg/24 hours for advanced-stage disease. Restless Legs Syndrome: Initially, 1 mg/24 hours, increased as needed by 1 mg/24 hours at weekly intervals, up to 3 mg/24 hours. Apply once a day to the skin, press firmly in place for 30 seconds. Do not place NEUPRO on oily, irritated, or damaged skin, or where it will be rubbed by tight clothing. Do not use the same site more than once every 14 days. The prescribed dose may be achieved using single or multiple patches. To discontinue treatment, reduce the dose gradually until complete withdrawal of NEUPRO.
Source: US FDA prescribing information
NEUPRO is contraindicated in patients who have demonstrated hypersensitivity to rotigotine or the components of the transdermal system. History of hypersensitivity to rotigotine or components of the transdermal patch.
Source: US FDA prescribing information
Contains sodium metabisulfite that may cause allergic-type reactions in those with sulfite sensitivity. Falling asleep during activities of daily living, including the operation of motor vehicles, and somnolence may occur. Hallucinations/psychosis and dyskinesia may occur. Symptomatic postural hypotension and syncope may occur, especially during dose escalation. Consider dose reduction or stopping NEUPRO if patient develops compulsive behaviors. Elevation of blood pressure and heart rate may occur. Application site reactions can occur and may be severe. Hyperpyrexia and confusion may occur with sudden discontinuation or dose reduction.
Source: US FDA prescribing information
The following serious adverse reactions are discussed below and elsewhere in the labeling: Sulfite Sensitivity Falling Asleep During Activities of Daily Living and Somnolence Hallucinations/Psychosis Symptomatic Hypotension Syncope Impulse Control/Compulsive Behaviors Elevation of Blood Pressure and Heart Rate Weight Gain and Fluid Retention Dyskinesia Application Site Reactions Augmentation and Rebound in RLS Hyperpyrexia and Confusion Withdrawal Symptoms Fibrotic Complications Parkinson's disease: Most common adverse reactions (at least 5% greater than placebo) were nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, disturbances in initiating and maintaining sleep, hyperhidrosis, visual disturbance, peripheral edema, and dyskinesia.
Source: US FDA prescribing information
Dopamine Antagonists Dopamine antagonists, such as antipsychotics or metoclopramide, may diminish the effectiveness of NEUPRO.
Source: US FDA prescribing information
Store at 20° - 25°C (68° - 77°F), excursions permitted between 15° - 30°C (59° - 86°F). NEUPRO should be stored in the original pouch. Do not store outside of pouch.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Rotigotine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Neupro 1 mg/24 hours transdermal patchTransdermal | UCB | US FDA | Available on request |
| Neupro 2 mg/24 hours transdermal patchTransdermal | UCB | US FDA | Available on request |
| Neupro 3 mg/24 hours transdermal patchTransdermal | UCB | US FDA | Available on request |
| Neupro 4 mg/24 hours transdermal patchTransdermal | UCB | US FDA | Available on request |
| Neupro 6 mg/24 hours transdermal patchTransdermal | UCB | US FDA | Available on request |
| Neupro 8 mg/24 hours transdermal patchTransdermal | UCB | US FDA | Available on request |
| Neupro kit | UCB | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Rotigotine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Rotigotine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Rotigotine, including Neupro.
Yes. The US FDA first approved Rotigotine on 9 May 2007, according to Drugs@FDA.
Yes. Rotigotine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Rotigotine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Rotigotine is classified under ATC code N04BC09 (Rotigotine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.